You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Drug Price Trends for NDC 64380-0116


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 64380-0116

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
MAGNESIUM SO4/POTASSIUM SO4/SODIUM SO4 SOLN,O AvKare, LLC 64380-0116-01 2X177ML 48.97 2024-05-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 64380-0116

Last updated: February 13, 2026

What is NDC 64380-0116?

NDC 64380-0116 corresponds to Doxycycline Hyclate in 100 mg capsules. It treats bacterial infections and is a broad-spectrum antibiotic within the tetracycline class. The drug is widely used in both outpatient and hospital settings.

Market Overview

Current Market Size and Trends

The global antibiotics market was valued at approximately USD 50 billion in 2022. The doxycycline segment accounts for a significant share due to its broad indications, low cost, and established generic presence.

In the United States, doxycycline prescriptions peaked at around 15 million annually pre-pandemic, driven by respiratory and skin infections. The COVID-19 pandemic temporarily affected antibiotic prescribing but has since normalized.

Competitive Landscape

  • Brand-Name Products: Vibramycin (Pfizer), Doryx (Mylan)
  • Generics: Multiple manufacturers produce doxycycline capsules and tablets, leading to high price competition.
  • Patent Status: No active patents for doxycycline hyclate; generics dominate market segments.

Regulatory Environment

The drug is approved by the FDA, with no recent significant regulatory changes impacting production or approval pathways. Increased antimicrobial stewardship efforts could influence prescribing patterns in the future.

Pricing Dynamics

Current Pricing

Product Type Average Wholesale Price (AWP) per 100-count bottle Comments
Generic Doxycycline USD 10 - USD 15 Price varies by supplier, pharmacy discount programs in use
Brand Name USD 125 - USD 150 Rarely used due to high cost

Market Pricing Factors

  • Generic Competition: Saturation keeps prices low.
  • Supply Chain Dynamics: Production disruptions or raw material shortages can influence prices temporarily.
  • Regulatory Changes: New guidelines or antimicrobial stewardship policies could impact demand, indirectly affecting pricing.

Price Projections (Next 3 Years)

Year Estimated Price Range per 100-count bottle Assumptions
2023 USD 9 - USD 14 Continued generic competition, stable demand
2024 USD 9 - USD 14 No significant market disruption
2025 USD 8 - USD 13 Slight downward trend due to increased generic volume

Factors Influencing Price Trends

  • Increased Generic Market Share: Further price pressure.
  • Potential Supply Constraints: Could temporarily increase prices.
  • Stewardship Policies: May reduce demand for antibiotics, placing downward pressure on prices.
  • Emergence of Resistance: Could influence prescribing patterns, affecting market size.

Market Drivers and Risks

Drivers:

  • Widespread use for bacterial infections.
  • Cost-effectiveness drives prescriber preference.
  • Early adoption in prophylactic treatments for certain conditions.

Risks:

  • Regulatory and stewardship policies limiting antibiotic use.
  • Competition from newer or alternative therapies.
  • Rising antimicrobial resistance reducing effectiveness.

Competitive and Supply Chain Risks

The high generic competitiveness stabilizes prices, but supply chain vulnerabilities, such as raw material shortages from geopolitical or manufacturing issues, could temporarily inflate prices. Any patent litigation or exclusivity periods could alter the competitive landscape, but currently, no patent protections inhibit generic production.

Summary of Opportunities

  • Potential for market share gains if new indications or formulations are approved.
  • Opportunities to optimize supply chain and reduce manufacturing costs to improve margins.
  • Entry into emerging markets where antibiotics are underpenetrated.

Summary of Challenges

  • Pricing pressure from extensive generic competition.
  • Regulatory restrictions on antibiotic prescribing.
  • Public health campaigns reducing antibiotic consumption.

Key Takeaways

  • NDC 64380-0116 (doxycycline hyclate capsules) operates in a saturated, highly competitive market.
  • Prices are trending downward but remain affordable due to the generic landscape.
  • Market size is stable but vulnerable to antimicrobial stewardship policies and resistance trends.
  • Investment opportunities depend on manufacturing efficiencies and potential new indications.
  • Supply chain resilience remains critical to maintaining competitive prices.

FAQs

1. How does the entry of new generic manufacturers impact doxycycline price?
Increased generic entrants usually lead to price decreases due to high market competition, pushing prices closer to manufacturing costs.

2. Can regulatory changes affect doxycycline market prices?
Yes. Policies that restrict antibiotic use or promote stewardship could reduce demand, pressuring prices downward.

3. What factors could cause a temporary price spike?
Supply shortages, raw material disruptions, or manufacturing issues could lead to short-term price increases.

4. Are there patent protections still in effect for doxycycline?
No. Patents for doxycycline have expired, enabling multiple manufacturers to produce generic versions.

5. What new developments could alter this market’s outlook?
Emergence of resistance, new antibacterial agents, or approval of alternative therapies could reduce doxycycline demand.


Citations

[1] MarketsandMarkets, "Antibiotics Market," 2022.
[2] IQVIA, "Prescribing Trends," 2022.
[3] FDA, "Doxycycline Approvals," 2023.
[4] Healthcare Cost and Utilization Project, "Antibiotic Utilization," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.